We deliver insights
through partnerships.


Early Access for


From primary to outpatient care, it is currently difficult for physicians to assess those with chronic liver disease. Physicians need a better tool to measure liver tissue stiffness and attenuation, and Sonic Incytes offers a convenient, comfortable and accessible solution for this need.

Sonic Incytes partners with medical care and research centers to determine the utility of Velacur™️ in various patient populations, and how it can be better integrated into various clinical settings.

Improving Pharma

Clinical Trials

For companies looking to treat chronic liver disease with new drugs, Sonic Incytes provides an accessible and affordable tool for measuring liver stiffness and attenuation.

Sonic Incytes is interested in partnering with pharma to screen patients for NASH clinical trials and measure changes in tissue stiffness and attenuation to monitor therapeutic effectiveness of promising NASH drugs.

Reducing Payer Risks

and Costs

For payers looking to reduce the growing costs associated with the increased prevalence of chronic liver disease, Sonic Incytes provides a tool that can be used in conjunction with other clinical indicators for assessing liver disease.

We are helping them assess disease prevalence in insured populations and mitigate future costs through early intervention.

The team has cultivated strong relationships with local and global centers of excellence in medical care and clinical research, pharmaceutical companies, and payers to tailor our technology for the benefit of patients worldwide.

Interested in
becoming a partner?

If you are interested in partnering with us, please get in touch.

Keep up with us

Stay up to date with our latest news.